ZhongMei Capital is a buy-out fund focused on sourcing and acquiring the US rights to early-stage biopharmaceutical assets originating in China. We then form a US NewCo to house the assets and generate clinical data in the United States in accordance with FDA guidelines. We provide value to our inve... Read more